2023-10-11 11:51:06 ET
DENVER, Colo., Oct 11, 2023 ( www.247marketnews.com )- Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has been running since announcing, this morning, the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts on October 11th -15th
After gapping higher to open at $1.57, it hit a $2.25 high, and is trading at $2.20, up $0.81 (+58.27%), on 23,374,120 shares traded. The first wave was basically from the $1.60 level to the $1.90, where it consolidated, followed by its move to the $2.20 level. It’s early enough in the session that it may have another wave or two to go.
Its 52-week range is $0.56 to …
The post Phio Pharmaceuticals Completes Second Intraday Wave on INTASYL Compound PH-894 News appeared first on 24/7 Market News .
For further details see:
Phio Pharmaceuticals Completes Second Intraday Wave on INTASYL Compound PH-894 News